NOVAVAX

Newfangled COVID-19 vaccines have left many people yearning for an old-school alternative. The one from Novavax could fit that bill.

If the FDA committee endorses Novavax's shot, the drug regulator is almost certain to rapidly authorize it for use in the U.S.

These are the stocks posting the largest moves in midday trading.

The stocks making the biggest moves in premarket trading include Peloton, Novavax, Vroom, and more.

Bearish investor sentiment continued to weigh on the major averages earlier on Monday.

Novavax reported net income of $203 million in the first quarter, compared to a net loss of $222.7 million the same period last year.

The meetings are a sign that the vaccines are moving closer to a possible authorization.

Novavax plans to move forward with a phase two trial this year to confirm the dosing levels, and a phase three during the 2023 flu season at the earliest.

Japan’s health ministry has approved Novavax’s COVID-19 vaccine, and people could start getting the shots by late May.

These are the stocks posting the largest moves before the bell.

The pharmaceutical developer Novavax says it has asked the European Medicines Agency to extend the authorization of its coronavirus vaccine to children aged 12 to 17 amid a surge of disease across the continent

The pharmaceutical developer Novavax says it has asked the European Medicines Agency to extend the authorization of its coronavirus vaccine to children aged 12 to 17 amid a surge of disease across the continent.

The company behind a COVID-19 vaccine touted as a key tool for the developing world will miss a target for giving doses to the U.N.-backed effort to deliver shots to poorer countries.

See which stocks are posting big moves after the bell on Monday, Feb. 28.

Moderna dropped more than 12%, the biggest decline in the S&P 500 as of Monday afternoon.

Novavax says its COVID-19 vaccine is proving safe and effective for kids as young as 12.

Croc in Indonesia freed from tire after 6 years

The stocks making the biggest moves in premarket trading include Peloton, Novavax, Harley-Davidson, and more.

There are two major developments involving the COVID-19 vaccines.

Novavax's shots are based on a kind of "protein subunit" technology that has been used for decades in other routine vaccinations.

Novavax's shots are based on a kind of "protein subunit" technology that has been used for decades in other routine vaccinations.

The vaccine-maker expects feedback from American regulators in February.

These are the stocks posting the largest moves in midday trading.

These are the stocks posting the largest moves in midday trading.

These are the stocks posting the largest moves before the bell.

The European Union’s executive commission has authorized a fifth COVID-19 vaccine for use in the 27-nation bloc Monday.

Protein subunit vaccines work by injecting people with a tiny portion of a virus. In the case of the COVID-19 vaccine, that tiny portion is the spike protein that the coronavirus uses to enter cells.

Biotechnology company Novavax says that Indonesia has given the world’s first emergency use authorization for its COVID-19 vaccine, which uses a different technology than current shots.

These are the stocks posting the largest moves before the bell.

Britain says it it will offer new vaccinations to thousands of people who volunteered for trials of the Novavax coronavirus vaccine, which has not yet been approved for use in any country.

The decision means thousands of people who took part in trials will be able to travel abroad.

The stocks making the biggest moves in premarket trading include Tesla, Moderna, Novavax, GM, and more.

Health-care stocks ended last week divided. Market analysts are divided, too.

About 50,000 Americans volunteered for Novavax and AstraZeneca COVID vaccine trials but the companies haven't asked the FDA they be cleared for use.

Vaccine maker Novavax is asking regulators in India, Indonesia and the Philippines to allow emergency use of its COVID-19 shot.

Since the coronavirus pandemic began, Dr. Frank McGeorge has been keeping viewers up-to-date and informed on all fronts.

Persistent hype around mRNA vaccine technology is now distracting us from other ways to end the pandemic.

A fourth U.S.-based COVID-19 vaccine has proven effective in preventing serious illness from coronavirus, according to Phase 3 data from the company, Novavax. The two-dose Novavax shot had a 90.4% efficacy in trials using nearly 30,000 participants, including 100% efficacy against moderate and severe COVID-19 illness. Whether the shot will have the same path to getting emergency use authorization in the U.S. as the three prior vaccine company remains to be seen. Unlike the mRNA vaccines, the Novavax shot wouldn’t require the same cold storage that has caused struggles for some providers. As of Monday, June 21, nearly 4.8 million Michigan residents had gotten a first dose of COVID-19 vaccine, or 55.8% of residents 12 and older.

The stocks making the biggest moves in premarket trading include CureVac, The Honest Company, Fisker, and more.

Novavax said that its COVID vaccine is 90% effective overall and 100% effective at preventing moderate and severe disease.

Here’s what you missed on Local 4 News at 4:

Since it only needs normal refrigeration, this two-dose shot could be helpful in reaching rural areas.

The company also said its vaccine did well against variants. It's expected to play an important role in boosting vaccine supplies in the developing world.

These are the stocks posting the largest moves before the bell.

U.S. stock futures were flat Monday after the S&P 500 eked out another record close Friday.

In a large scale study, Novavax said its vaccine was completely effective against the original coronavirus strain and also effective against some variants. It works differently than other vaccines.

In a large-scale study, Novavax said its vaccine was completely effective against the original coronavirus strain and also effective against some variants. It works differently than other vaccines.

The company also said its vaccine did well against variants. It's expected to play an important role in boosting vaccine supplies in the developing world.

Novavax's study involved nearly 30,000 people ages 18 and up in the U.S. and Mexico.

Vaccine maker Novavax says its shot is highly effective against COVID-19 and also protects against variants.

Vaccine maker Novavax said Monday its shot was highly effective against COVID-19 and also protected against variants in a large, late-stage study in the U.S. and Mexico. The vaccine was about 90% effective overall and preliminary data showed it was safe, the company said. While demand for COVID-19 shots in the U.S. has dropped off dramatically, the need for more vaccines around the world remains critical.

If Novavax's vaccine is authorized, it would follow three Covid shots already approved for emergency use in the U.S. from Pfizer-BioNTech, Moderna and J&J.

A different kind of COVID-19 vaccine is coming, and it could be 'even more protective'

The findings will help scientific advisers decide if re-vaccinating people in the autumn is necessary.

Check out the companies making headlines in midday trading.

The stocks making the biggest moves in premarket trading include Virgin Galactic, Callaway Golf, Palantir, and more.

The U.S. is now averaging about 40,000 new coronavirus cases per day. India is averaging 350,000. Here's the latest COVID news.

We’ve heard that COVID-19 vaccines are not mix and match and that both doses are needed from the same vaccine. But a study is underway in the United Kingdom to see if that might be possible or even preferable.

Three vaccines are authorized for use in the United States and another two are coming soon. Here is a closer look at what we know so far:

She's one of the lead vaccine scientists at Novavax, a Maryland biotech company in the final trials of its COVID-19 vaccine. Her team isn't just led by a woman, it's almost all women. "I was told I was one of the first people to open a vial of the vaccine," Corbett said. Evan Vucci / APPatel has a theory as to why women are at the forefront: "We have a power inside us. Before the pandemic, the number of women in science and engineering was rising, up 36% over the past decade.

Ulta Beauty — Shares of the cosmetics company fell more than 6% after reporting full-year same-store sales and revenue guidance below Wall Street estimates. Netflix — Shares of the streaming service slipped 1.8% after Netflix announced it would be testing a crackdown on password sharing. According to people with knowledge of the matter, the fine could exceed the $975 million fine that Qualcomm paid in 2015. JMP Securities praised the quarter in a note to clients but did point out that billings growth decelerated quarter over quarter. The company however, reported revenue that topped analyst estimates.

Check out the companies making headlines before the bell:Ulta Beauty (ULTA) – Ulta Beauty announced that CEO Mary Dillon will step down in June to be replaced by company President David Kimbell. Separately, the cosmetics retailer beat estimates on the top and bottom lines for its latest quarter, but did cut its fiscal 2021 comparable sales outlook. Ulta lost 8.2% in premarket trading. Poshmark (POSH) – Poshmark reported better-than-expected sales for its latest quarter, but the online retailer of secondhand goods issued a current-quarter forecast that was short of analyst estimates. Vail did say visitation trends improved throughout the quarter, and shares surged 9.7% premarket.

Novavax — Shares of Novavax slipped more than 15% after missing on the top and bottom lines of its quarterly results. Novavax reported a loss of $2.70 per share, compared to the loss of $1.49 per share expected on Wall Street, according to Refinitiv. The company said sales reached $127.7 million during the period, short of the expected $131.3 million, according to analysts surveyed by Refinitiv. Analysts expected earnings per share of $2.54 on revenue of $27.48 billion. Analysts polled by Refinitiv expected earnings per share of $1.01 on revenue of $5.86 billion.

Take a look at some of the biggest movers in the premarket:Zoom Video (ZM) – Zoom reported quarterly profit of $1.22 per share, beating the consensus estimate of 79 cents a share. Target (TGT) – The retailer reported quarterly earnings of $2.67 per share, 13 cents a share above estimates. Kohl's (KSS) – Kohl's reported quarterly profit of $2.22 per share, including $1.15 a share in incremental tax benefits. Nio (NIO) – Nio fell 5.2% in premarket trading after it reported a larger-than-expected loss for its latest quarter. AutoZone (AZO) – The auto parts retailer reported quarterly profit of $14.93 per share, beating the consensus estimate of $12.84 a share.

LONDON – U.S.-based Novavax has begun a late stage trial of its potential COVID-19 vaccine in the United Kingdom because the high-level of the coronavirus circulating in the country is likely to produce quick results, the pharmaceutical company said. Novavax plans to test the effectiveness of its vaccine in a trial involving 10,000 people between the ages of 18 and 84, according to a statement issued late Thursday. The trial is being conducted in partnership with the U.K. government’s Vaccine Taskforce, which was created in April to help speed the development of a COVID-19 vaccine. The U.K. has already agreed to buy 60 million doses of the Novavax vaccine to ensure it can be distributed as quickly as possible if it is approved by regulators. The government said Friday that participants in the Novavax trial will be drawn from the 250,000 people who have volunteered to take part in COVID-19 vaccine testing through the National Health Service’s Vaccine Registry.

Despite the rally, the S&P 500 still posted its fourth straight weekly loss, extending Wall Street's September swoon. The S&P 500 rose 1.6% after flip-flopping between small gains and losses a few times in the early going. The S&P 500 came within striking distance of a 10% drop from its all-time high earlier this week, what Wall Street calls a correction. The S&P 500 rose 51.87 points to 3,298.46. Norwegian Cruise Line notched the biggest gain in the S&P 500, vaulting 13.7%.

The directive comes amid concerns about an uptick in coronavirus cases in certain Brooklyn and Queens neighborhoods with large Orthodox Jewish populations. New York City’s current overall infection rate remains low, but official figures indicate the affected neighborhoods accounted for 20% of the city’s coronavirus cases in recent weeks. ___BOSTON — An outbreak of coronavirus infections at a major Boston hospital has grown to 19 confirmed cases. ___DES MOINES, Iowa — Iowa has reported a jump of 1,086 new coronavirus cases, the second consecutive day of new cases exceeding 1,000. There are currently nearly 985,000 worldwide coronavirus deaths.

WASHINGTON The White House says President Donald Trump will visit North Carolina on Monday to tour a business that is participating in work on a COVID-19 vaccine. The White House said Trump is expected to speak about the collaboration between the administration and the private sector to rapidly develop a vaccine and ensure rapid distribution once ready. North Carolina is a key battleground state in the coming election, and Trumps visit marks his 10th trip to the state during his presidency. The biotechnology facility Trump will visit is the FUJIFILM Diosynth Biotechnologies Innovation Center in Morrisville, a suburb of Raleigh. The White House said the company is manufacturing key components of a COVID-19 vaccine candidate being developed by Novavax, an American vaccine development company based in Maryland.

In this photo released by Nucleus Network/ABC, clinical trial participants are given a coronavirus vaccine in Melbourne, Australia, Tuesday, May 26, 2020, with hopes of releasing a proven vaccine this year. Novavax will inject 131 volunteers in the first phase of the trial testing the safety of the vaccine and looking for signs of its effectiveness. (Patrick Rocca/Nucleus Network/ABC via AP)CANBERRA A U.S. biotechnology company began injecting a coronavirus vaccine candidate into people in Australia on Tuesday with hopes of releasing a proven vaccine this year. Novavax used genetic engineering to grow harmless copies of the coronavirus spike protein in giant vats of insect cells in a laboratory. The way we make a vaccine is we never touch the virus, Novavax told The Associated Press last month.